Liposome-based drug delivery to alveolar macrophages

Bibliography

• FARR SJ, KELLAWAY IW, CARMAN-MEAKING B: Assessing the potential of aerosol generated liposomes from pressurized pack formulations. J. Control. Rel. (1987) 5:119-127.
   Google Scholar
• VYAS SP, SAKTHIVEL T: Pressurized pack-based liposomes for pulmonary targeting of isoprenaline--development and characterization. J. Microencapsul. (1994) 11(4):373-380.
   PubMed Web of Science ®Google Scholar
• VYAS SP, DIXIT VK: Macrophage targeting and colloidal drug carriers In: Advances in Lipsomal Research. CBS Publishers and Distributors, New Delhi (2000):98-120.
   Google Scholar
• BRAJTBURG J, POWDERLY WG, KOBAYASHI GS, MEDOFF G: Amphotericin B: delivery systems. Antimicrob. Agents. Chemother. (1990) 34:381-384.
   PubMed Web of Science ®Google Scholar
• GILBERT BE, WYDE PR, WILSON SZ: Aerosolised liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob. Agents. Chemother. (1992) 36(7):1466-1471.
   PubMed Web of Science ®Google Scholar
• GILBERT BE, WYDE PR, LOPEZ-BERESTEIN G, WILSON SZ: Aerosolised amphotericin B-liposomes for treatment of systemic Candida infections in mice. Antimicrob. Agents Chemother. (1994) 38(2):356-359.
   PubMed Web of Science ®Google Scholar
• GAVALDA J, MARTIN MT, LOPEZ P et al.: Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Anitimicrob. Agents Chemother. (2005) 49(7):3028-3030.
   PubMed Web of Science ®Google Scholar
• RUIJGROK EJ, VULTO AG, VAN ETTEN EW: Efficacy of aerosolised amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J. Antimicrob. Chemother. (2001) 48(1):89-95.
   PubMed Web of Science ®Google Scholar
• RUIJGROK EJ, VULTO AG, VAN ETTEN EW: Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (Amp Bisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J. Pharm. Pharmcol. (2000) 52(6):619-627.
   PubMed Web of Science ®Google Scholar
• VYAS SP, QURAISHI S, GUPTA S, JAGANATHAN KS: Aerosolised liposome-based delivery of amphotericin B to alveolar macrophages. Int. J. Pharm. (2005) 296:12-25.
   PubMed Web of Science ®Google Scholar
• OWAIS M, AHMED I, KRISHNAKUMAR K, JAIN RK, BACHHAWAT BK, GUPTA CM: Tuftsin-bearing liposomes as drug vehicles in treatment of experimental aspergillosis. FEBS Lett. (1993) 326:56-58.
   PubMed Web of Science ®Google Scholar
• AHSAN F, RIVAS IP, KHAN MA, TORRES SUAREZ AI: Targeting to macrophages: Role of physicochemical properties of particulate carriers – liposomes and microspheres – on the phagocytosis by macrophages. J. Control. Rel. (2002) 79:29-40.
   PubMed Web of Science ®Google Scholar
• LAMBROS MP, BOURNE DW, ABBAS SA, JOHNSON DL: Disposition of aerosolised liposomal amphotericin B. J. Pharm. Sci. (1997) 86(9):1066-1069.
   PubMed Web of Science ®Google Scholar
• CHONO S, TANINO T, SEKI T, MORIMOTO K: Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J. Drug Target. (2006) 14(8):557-566.
   PubMed Web of Science ®Google Scholar
• VYAS SP, KANNAN ME, JAIN S, MISHRA V, SINGH P: Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. (2004) 269:37-49.
   PubMed Web of Science ®Google Scholar
• AGARWAL A, KANDPAL H, GUPTA HP, SINGH NB, GUPTA CM: Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob. Agents. Chemother. (1994) 38:588-593.
   PubMed Web of Science ®Google Scholar
• DEOL P, KHULLER GK: Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta (1997) 1334:161-172.
   PubMed Web of Science ®Google Scholar
• DEBS RJ, BLUMENFELD W, BRUNETTE EN et al.: Successful treatment with aerosolised pentamidine of Pneumocystis carinii pneumonia in rats. Antimicrob. Agents. Chemother. (1987) 31(1):37-41.
   PubMed Web of Science ®Google Scholar
• WONG JP, YANG H, BLASETTI KL, SCHNELL G, CONLEY J, SCHOFIELD LN: Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Rel. (2003) 92(3):265-273.
   PubMed Web of Science ®Google Scholar
• GOLDBACH P, DUMONT S, KESSLER R, POINDRON P, STAMM A: In situ activation of mouse alveolar macrophages by aerosolised liposomal IFN-γ and muramyl tripeptide. Am. J. Physiol. (1996) 270(3 Pt 1):L429-L434.
   PubMed Web of Science ®Google Scholar
• BAKKER J, SANDERS A, ROOIJEN NV: Effects of liposome-encapsulated drugs on macrophages: comparative activity of the diamidine 4’,6-diamidino-2-phenylindole and the phenanthridinium salts ethidium bromide and propidium iodide. Biochim. Biophys. Acta. (1998) 1373:93-100.
   PubMed Web of Science ®Google Scholar